Evolva Holding SA

EVE

CH1262055788

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:31:55 2024-05-08 am EDT			5-day change	1st Jan Change
0.99 ^CHF	+9.76%		+1.02%	+37.50%

Apr. 15	Evolva Shareholders Pass Resolutions to Revoke Liquidation, Delisting	MT
Mar. 26	Evolva Secures Temporary Exemption from Listing Rules Amid Liquidation	MT

Evolva Holding SA Provides Sales Guidance for the Full Year 2018

November 09, 2018 at 01:01 am EST

Evolva Holding SA provided sales guidance for the full year 2018. For the full year 2018, the company expects product sales to grow at a high double digit percentage rate.

Latest news about Evolva Holding SA

Evolva Shareholders Pass Resolutions to Revoke Liquidation, Delisting	Apr. 15	MT
Evolva Secures Temporary Exemption from Listing Rules Amid Liquidation	Mar. 26	MT
Evolva Closes CHF20 Million Unit Sale to Lallemand's Danstar Ferment	Dec. 28	MT
Danstar Ferment AG completed the acquisition of Evolva AG form Evolva Holding SA.	Dec. 27	CI
Evolva Shareholders OK Unit Sale, Proposed Liquidation	Dec. 22	MT
Evolva to Seek Shareholder Nod for Unit Sale, Proposed Liquidation	Nov. 30	MT
Evolva Strikes CHF20 Million Deal to Sell Business to Lallemand's Danstar Ferment	Nov. 21	MT
Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA for CHF 30 million.	Nov. 20	CI
Evolva, Breko Sign Distribution Deal for Dietary Supplement Ingredient	Nov. 14	MT
Evolva and Breko GmbH Broaden Partnership by Signing Agreement for the Exclusive Distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam	Nov. 14	CI
Evolva Signs Distribution Deal with Chemical Group Lehvoss	23-09-28	MT
Evolva and LEHVOSS Sign Agreement for Distribution of Veri-teTM Resveratrol in over A Dozen European Countries	23-09-28	CI
Evolva, Nice & Green Agree to Term Amendments for CHF5 Million Facility	23-09-13	MT
Evolva Wins Thai Regulatory Nod for Nature-based Ingredient Veri-teTM Resveratrol	23-09-06	MT
Evolva Receives Approval for Veri-Te Resveratrol in Thailand	23-09-06	CI
Evolva Shareholders Greenlight Proposed Conditional Capital Increase Under New Financing Deal	23-08-24	MT
Transcript : Evolva Holding SA, H1 2023 Earnings Call, Aug 24, 2023	23-08-24
Evolva Posts Larger H1 Loss; Revenue Slides Down	23-08-24	MT
Evolva Holding SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Evolva Gets Approval for Veri-te Resveratrol Use in Taiwan	23-07-25	MT
Evolva Receives FDA Approval for Veri-teTM Resveratrol in Taiwan	23-07-25	CI
SIX Group Makes Index Adjustments Following Review	23-07-11	MT
Global markets live: Nvidia, IBM, Ford, Pfizer, Lucid Group...	23-06-26
Evolva Secures New Financing Until 2023-end	23-06-26	MT
Evolva Withdraws FY23 Guidance Amid Strategic Financing Review	23-06-14	MT

Evolva Holding SA (Evolva) is a Switzerland-based biotechnology company reseaching, developing and commerzializing nature-based ingrendients. The activity of the Company is divided into two segments: technololgy platforms - combines biology with technology to produce nature-based ingredients; technology servises- provides tailored services to clients across industries. The Company is focused on developing and increase the yield and efficiency of the production of various ingredients.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOLVA HOLDING SA	+37.50%	7.17M
MODERNA, INC.	+22.77%	46.4B
IQVIA HOLDINGS INC.	-1.42%	41.75B
LONZA GROUP AG	+48.83%	41.37B
CELLTRION, INC.	-3.42%	29.71B
ICON PUBLIC LIMITED COMPANY	+10.23%	26.01B
ALNYLAM PHARMACEUTICALS, INC.	-19.58%	19.52B
MEDPACE HOLDINGS, INC.	+26.43%	12.43B
BIO-TECHNE CORPORATION	-0.03%	12.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.51%	12.13B

Other Biotechnology & Medical Research